Palantir Pharma: mitigating R&D risk through data fusion

With development times of ten years or more and costs of over $1 billion per new medicine, pharmaceutical R&D is an expensive, lengthy, and risky process. Enterprises can minimize the risk associated with drug development programs by better understanding the universe of data relevant to particular diseases, targets, and drug candidates. Unfortunately, achieving this level of [...]

Continue reading »

Using Palantir to Explore Prescription Drug Safety

Drug safety is a serious concern in the United States with adverse drug events contributing to over 770,000 injuries and deaths per year. Cost estimates range from $1.5 to $5.6 billion annually. The FDA closely monitors these adverse events and releases communications and advisories depending on the severity and frequency of the events. The FDA [...]

Continue reading »